Intellia Therapeutics Ends Co-Development Agreement With Regeneron
By Chris Wack
Intellia Therapeutics said in a filing that it has notified Regeneron Pharmaceuticals that it is opting out of its Factor IX co-development and co-funding agreement, which Intellia and Regeneron entered into in May 2020.
The agreement will end 180 days after Intellia's written notice to Regeneron, and the company will continue to have obligations related to the co-development of gene-editing products directed to Factor IX until the effective date of termination.
Upon termination, Intellia will no longer be obligated for sharing 35% of the development costs, or be entitled to receive 35% of the profits, for gene-editing products.
Intellia will continue to support Regeneron with the development of gene-editing products under a previous license and collaboration agreement.
Write to Chris Wack at chris.wack@wsj.com
(END) Dow Jones Newswires
March 22, 2024 10:23 ET (14:23 GMT)
Copyright (c) 2024 Dow Jones & Company, Inc.-
Small-Cap and Value Stocks Are Undervalued
-
Why We Expect the Job Market’s Slowdown to Renew in 2024
-
5 Undervalued Stocks to Buy to Play a Little Defense
-
Markets Brief: AI Leaders Excel In Earnings Season So Far
-
What History Tells Us About the Fed’s Next Move
-
What’s Happening In the Markets This Week
-
Alphabet’s New Dividend: What Investors Need to Know
-
Going Into Earnings, Is Palantir Stock a Buy, a Sell, or Fairly Valued?
-
SiriusXM Earnings: Decent Results With Plan for Technology and Content Investment to Drive Growth
-
Coca-Cola Earnings: Solid Volume On Innovation and Digital Engagement
-
Is Berkshire Hathaway a Buy Before the Annual Meeting?
-
Investment Opportunities in the Drug Distribution Industry
-
Why the End of Quantitative Tightening Matters
-
Eli Lilly Earnings: Strong Weight-Loss Drug Sales Expand Margins
-
After Earnings, Is Meta Stock a Buy, a Sell, or Fairly Valued?
-
After Earnings, Is Boeing Stock a Buy, a Sell, or Fairly Valued?